Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.

Acquisition of homozygous activating growth factor receptor mutations might accelerate cancer progression through a simple gene-dosage effect. Internal tandem duplications (ITDs) of FLT3 occur in approximately 25% cases of acute myeloid leukemia and induce ligand-independent constitutive signaling. Homozygous FLT3-ITDs confer an adverse prognosis and are frequently detected at relapse. Using a mouse knockin model of Flt3-internal tandem duplication (Flt3-ITD)-induced myeloproliferation, we herein demonstrate that the enhanced myeloid phenotype and expansion of granulocyte-monocyte and primitive Lin(-)Sca1(+)c-Kit(+) progenitors in Flt3-ITD homozygous mice can in part be mediated through the loss of the second wild-type allele. Further, whereas autocrine FLT3 ligand production has been implicated in FLT3-ITD myeloid malignancies and resistance to FLT3 inhibitors, we demonstrate here that the mouse Flt3(ITD/ITD) myeloid phenotype is FLT3 ligand-independent.

[1]  M. Levis,et al.  Further Activation of FLT3 Mutants by FLT3 Ligand , 2011, Oncogene.

[2]  B. Smith,et al.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. , 2011, Blood.

[3]  C. Pronk,et al.  Expression and role of FLT3 in regulation of the earliest stage of normal granulocyte-monocyte progenitor development. , 2010, Blood.

[4]  Y. Yatabe,et al.  Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer , 2010, The FEBS journal.

[5]  Calum MacAulay,et al.  Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells , 2009, PloS one.

[6]  S. Meshinchi,et al.  Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia , 2009, Clinical Cancer Research.

[7]  C. Peschel,et al.  Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy , 2009, Clinical Cancer Research.

[8]  K. Glaser,et al.  Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. , 2007, Blood.

[9]  T. Lister,et al.  Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. , 2008, Blood.

[10]  K. Hunt,et al.  Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression , 2008, Modern Pathology.

[11]  Heidi Dvinge,et al.  Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. , 2008, Cancer cell.

[12]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[13]  G. Ehninger,et al.  Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis , 2008, Cells Tissues Organs.

[14]  S. Hirota,et al.  A mouse model of a human multiple GIST family with KIT‐Asp820Tyr mutation generated by a knock‐in strategy , 2008, The Journal of pathology.

[15]  K. Takamiya,et al.  Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. , 2006, Blood.

[16]  S. Fröhling,et al.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. , 2007, Cancer cell.

[17]  S. E. Jacobsen,et al.  Critical role of FLT3 ligand in IL-7 receptor independent T lymphopoiesis and regulation of lymphoid-primed multipotent progenitors. , 2007, Blood.

[18]  David Bryder,et al.  Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. , 2007, Cell stem cell.

[19]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[20]  T. A. Lister,et al.  Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. , 2005, Cancer research.

[21]  C. Antonescu,et al.  A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. , 2005, Cancer research.

[22]  Chunaram Choudhary,et al.  AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. , 2005, Blood.

[23]  S. Morrison,et al.  Supplemental Experimental Procedures , 2022 .

[24]  Chunaram Choudhary,et al.  Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine Kinases , 2005, Molecular and Cellular Biology.

[25]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[26]  M. Fiscella,et al.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Goumans,et al.  A Gain of Function Mutation in the Activation Loop of Plateletderived Growth Factor β-Receptor Deregulates Its Kinase Activity* , 2004, Journal of Biological Chemistry.

[28]  S. E. Jacobsen,et al.  Enforced expression of cyclin D2 enhances the proliferative potential of myeloid progenitors, accelerates in vivo myeloid reconstitution, and promotes rescue of mice from lethal myeloablation. , 2004, Blood.

[29]  D. Hicklin,et al.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. , 2004, Blood.

[30]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[31]  Ø. Bruserud,et al.  Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. , 2003, Haematologica.

[32]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[33]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[34]  K. Deguchi,et al.  Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML , 2002, Leukemia.

[35]  M. Cosma,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Loss of Heterozygosity at the RET Protooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A* , 2022 .

[36]  I. Lubensky,et al.  Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. , 2000, Cancer research.

[37]  B. Pulendran,et al.  Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. , 2000, Blood.

[38]  A. Tischler,et al.  C‐cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B , 2000, The EMBO journal.

[39]  A. Bardelli,et al.  Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists , 1999, Oncogene.

[40]  S. Goff,et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.